BT-11 is a LANCL2-binding compound for treating inflammatory bowel disease. Oral treatment with BT-11 at 8 mg/kg/d in a mouse model of inflammatory bowel disease resulted in lowering the disease activity index, decreasing colonic inflammatory lesions, and suppressing inflammatory markers (e.g., TNF-α, and interferon-γ) in the gut.